Systemic understanding of protein phosphatase 2A (PP2A)-regulated cellular processes is still at infancy. Here, we present mass-spectrometry analysis of phospho-targets (dephosphorylome) regulated by PP2A modulation. In addition to PP2A-regulated processes and targets, the data reveal important general concepts and rules related to PP2A-mediated phosphoregulation.
Introduction
Serine/threonine phosphatase PP2A is essential for normal development 1 , and regulates large number of physiological and pathological processes ranging from immune responses 2 to Alzheimer´s disease 3 . PP2A is also a critical human tumor suppressor, inhibition of which is a prerequisite for malignant transformation of many types of normal human cells [4] [5] [6] [7] . PP2A inhibition promotes in vivo tumorigenesis [8] [9] [10] [11] [12] [13] , and orally bioavailable, and non-toxic, PP2A reactivating small molecule compounds show robust antitumor effects 14, 15 . Although PP2A has been recognized as critical regulator of several signaling pathways, and RAS-driven oncogenic signaling 6, 9, 16, 17 , the depth by which PP2A controls cell signaling have not been systematically addressed as yet.
PP2A is a trimeric protein complex (Fig. 1A ) in which a core dimer formed between the scaffolding A subunit (PPP2R1A, PPP2R1B) and the catalytic C subunit (PPP2CA, PPP2CB) is associated with one of the many B subunits that facilitate and direct the interaction of the trimer with substrate proteins 16 . In addition to mutations found in cancer, PP2A activity is regulated by various nongenomic mechanisms 18 including post-translational modifications of PP2A complex components, as well as by interaction with group of designated PP2A inhibitor proteins (PIPs hereafter). The best-characterized PIPs are CIP2A, PME-1, and SET ( Fig. 1A ) 4, 19, 20 . Despite their classification as PIPs, CIP2A, PME-1, and SET do not share structural features [21] [22] [23] , and the mechanisms by which they inhibit PP2A activity toward their selected phosphoprotein targets are vastly different. SET binds and directly inhibits the catalytic center of PP2Ac 24, 25 , whereas PME-1 regulates PP2Ac activity via demethylation of the Cterminal leucine 309 and through the direct eviction of metal ions from the catalytic center 20, 21 . CIP2A binds the PP2A complex via a direct interaction with the B56 regulatory subunits 23 . Importantly, despite their differential mode of PP2A regulation, the cancer-relevant phenotypes affected by CIP2A, PME-1 or SET modulation can be rescued by concomitant PP2A modulation 10, [26] [27] [28] , indicating that their function are truly dependent on PP2A. Tissue and cell type specific expression, and regulation of PIPs thus provides a sophisticated cellular mechanism to regulate the major Ser/Thr phosphatase PP2A.
However, currently we lack any systematic understanding of processes regulated by, or functional redundancy of these PP2A modulating proteins.
Also, the rules that determine functional consequences of PP2A modulation on cancer cellular signaling are very poorly understood.
In concert with involvement of PP2A in tissue homeostasis, recent studies have revealed also specific roles for PIPs in a number of physiological and pathological processes. Physiologically CIP2A promotes spermatogenesis 29 , T-cell activation 30 and intestinal regeneration in response to tissue damage 31 . PME-1 knock-out mice are perinatally lethal possibly due to problems with breathing and suckling behavior 32 , and PME-1 overexpression has been linked to increased Tau phosphorylation and Alzheimer´s disease progression 33 .
SET-mediated PP2A inhibition has instead been linked to natural killer cell activation 34, 35 . Notably, all these PIPs are commonly expressed at high levels in various cancer types, and inhibit PP2A phosphatase activity toward cancer-driving proteins. CIP2A in particular is a prevalently overexpressed oncoprotein across most human cancer types 9, 10, 26, 36 , and high CIP2A expression is a synergistic poor survival marker with RAS mutations and expression across TCGA pan-cancer data 37 . Inhibition of these three PIPs also effectively suppresses malignant cell growth and tumorigenesis in in vivo models 9, 10, 27, 28 .
Based on these characteristics, targeting of CIP2A, PME-1, and SET has recently emerged as an attractive novel therapeutic approach in cancers without PP2A mutations, particularly in combination with drugs that target phosphorylation-dependent signaling 4, 19, 27 . However, whether the role for PIPs and PP2A in defining drug responses can be generalized beyond thus far tested kinase inhibitors is yet unclear.
Here we report phosphoproteome analysis of HeLa cells where we have targeted the PP2A scaffold protein PPP2R1A and CIP2A, PME-1, or SET. The study provides the largest currently available resource for understanding the processes targeted by PP2A activity. In addition to novel information on PP2A-regulated processes and targets, the data also reveal important general concepts related to phosphatase biology. These include the unidirectionality paradigm and differential spatial distribution of kinase-and phosphatasedominated phosphotargets. An important implication of these findings is that deregulation of phosphatase activity alone can activate many established cancer relevant signalling pathways, particularly seen for MYC activity. Our data also demonstrate how PP2A dephosphorylome activity globally defines drug sensitivities. The insights provided by these results are important for holistic understanding of cell signaling but also may have translational relevance in light of emerging pharmacological approaches for PP2A activity modulation 14, 15, 38 in human diseases ranging from Alzheimer´s disease to cancer.
Results
Identification and quantification of the PP2A dephosphorylome via LC-
MS/MS
PPP2R1A is the predominant PP2A scaffold subunit, and essential for functional PP2A complex formation (Fig. 1A) . Therefore, HeLa cells were treated with three independent PPP2R1A siRNAs to simulate PP2A inhibition.
CIP2A, PME-1, and SET were targeted with independent siRNA sequences (3-4/gene) to characterize the phosphoproteomes that are regulated by three well characterized PIPs. HeLa cells were chosen as a model based on previous evidence of their robust but sub-lethal response to PP2A modulation 26, 37 .
Changes in peptide phosphorylation were analyzed 72 h after transfection via a previously described label-free phosphoproteomics method, combined with pairwise abundance normalization developed for accurate monitoring of global phosphorylation changes 37 ( Fig. S1A) . Importantly, the performance of the method was validated by high reproducibility between the phosphoproteomics data and phosphospecific antibody survey 37 .
Depletion of the PP2A scaffold PPP2R1A or PP2A inhibitor proteins results in global phosphorylation changes
In total, 7037 non-redundant phosphopeptides were quantified from the HeLa whole cell lysates. The reported PP2A dephosphorylome targets are limited to those that were quantified consistently across all replicate samples (Fig. S1D ).
Of the consistently quantified phosphopeptides, 43% were significantly regulated (5% FDR) by the selected manipulations, and 57% of the phosphoproteins had at least one differentially regulated phosphopeptide. The entire catalogue of differentially regulated phosphopeptides is included as Table S1 and will be available online at www.depod.org
Consistent with the role of PP2A as a potent serine/threonine phosphatase, depletion of the PP2A complex scaffold protein PPP2R1A resulted in a robust increase in the average phosphorylation level across the HeLa cell phosphoproteome (Fig. 1B, S1B-D) . Notably, only a minor subset of the phosphopeptides significantly regulated by PPP2R1A exhibited decreased phosphorylation ( Fig. 1C) , which indicates that global PP2A inhibition cannot be acutely compensated for by the increased activities of other serine/threonine phosphatases.
In contrast, cells that were deficient in any of the PIPs (i.e., CIP2A, PME-1 or SET) (Fig. 1A ) displayed global dephosphorylation (Fig. 1B , S1B-D). Depletion of either CIP2A or PME-1 caused similar overall increases in protein dephosphorylation, whereas SET clearly appeared to be the most robust inhibitor of protein dephosphorylation and significantly regulated 30.5% of the detected phosphopeptides (Fig. 1C) . Importantly, because only a minor subset of the phosphopeptides that were significantly regulated by PIPs (0.5-2.7%) exhibited increased phosphorylation (Fig. 1C) , these data also indicate that interference with serine/threonine dephosphorylation via SET, PME-1 and CIP2A inhibition cannot be acutely compensated for by increased kinase activities.
To address the outstanding question of the redundancy of CIP2A, PME-1 and SET in the regulation of global serine/threonine phosphorylation we assessed the degree of overlap between their dephosphorylome targets. In accord with a common regulatory mechanism of dephosphorylation inhibition (i.e., PP2A inhibition), 49% of the CIP2A targets were regulated also by PME-1, whereas 37% of PME-1-regulated targets were also CIP2A targets (Fig. 1D ). The nonredundant targets could be due to the differential selectivity of CIP2A and PME-1 for different PP2A trimer complexes 9, 23, 39 . On the other hand, SET clearly possessed the largest number of dephosphorylome targets; 534 targets were uniquely regulated by SET (Fig. 1D) . The larger number of SET targets compared to CIP2A and PME-1 may be at least partly due to the direct inhibition of the catalytic activity of PP2Ac by SET 24, 25 and the lack of selectivity towards specific B-subunit containing PP2A trimers, as is the case with PME-1 or CIP2A 9, 23, 39 . Moreover, it should be noted that many SET targets were indeed regulated to certain extent also by CIP2A and PME-1 depletion (Table S1 ), although these effects did not meet the selected statistical filtering criteria. This overlap of targets regulated by PIPs, together with the tendency toward the enrichment of the recently identified PP2A B56 subunit binding motif 40 among the most significantly regulated targets (Fig. S1E,F) , support the notion of common PP2A-related mechanistic basis of regulation.
Together, these data demonstrate that PP2A regulates a very large fraction of cancer cell phosphoproteome. The data also systematically validate the function of CIP2A, PME-1, and SET as cellular inhibitors of serine/threonine dephosphorylation, and provide the first systemic estimate of the degree of their biological redundancy.
PP2A-regulated cellular processes
We used g:Profiler software 41 to systematically analyze the most enriched processes in the differentially regulated phosphoproteomes of PPP2R1A, CIP2A, PME-1, and SET. The identified PP2A target processes were found to cover large spectrum of cellular functions ( Fig. 2A ), but to contain large number of proteins for which there has not previously been evidence for PP2A-mediated regulation (Table S1 ).
Among targets involved in "regulation of cell cycle" we identified examples indicating cross talk between human tumor suppressors PP2A and TP53. SET depletion inhibited phosphorylation of TP53 (serine (S)392; Table S1 ) and both PPP2R1A and SET regulated MYBBP1A (S1303, S1308), which is involved in TP53 activation via acetylation and functions as a tumor suppressor for RASinduced transformation 42 . Another SET target PML (S518, S527) instead controls TP53 acetylation and transcriptional activity 43 . Other novel SETspecific targets in cell cycle and mitosis regulation included CDC23 (S588, S596), anaphase-promoting complex (APC) subunit CDC26 (S42), and mitotic aurora kinase target BOD1L (S482, S2779, S2964, S2986).
Among the splicing factors with established functional relevance in cancer 44 , we identified a total of 6 proteins and 8 phospho-sites that were significantly regulated by PPP2R1A (Fig. 2B , and Table S1 ). While these cancer-relevant splicing factors were predominantly regulated by PPP2R1A, a distinct set of mRNA processing and splicing factors was found to be dephosphorylated upon depletion of the PIPs (Fig. 2B ).
Among "nuclear envelope" proteins, we confirmed the regulation of many established LMNA PP2A target sites (Table S1 and Fig. 2C ). This is consistent with the associations of CIP2A
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, PME-1 45 , and PPP2R1A (Fig. 2C insert) with LMNA. We also discover phosphoregulation of LMNB1, LMNB2 and nuclear pore proteins (NUPs), including NUP98 by PPP2R1A and PIPs (Fig.   2C ). Additionally, SET depletion induced the dephosphorylation of LAP2A, LAP2B and EMERIN, whereas CIP2A and PME-1 exhibited more selective roles in the phosphoregulation of these nuclear lamina anchor proteins (Table   S1 and Fig. 2C ).
In summary, our analysis uncovers hundreds of novel PP2A targets associated with large number of cellular processes, many of which are deregulated in cancer. Based on this data, PP2A´s role in controlling cell behavior extends far beyond its currently understood role in controlling kinase pathways, mitosis 46 , and critical signaling nodes in cancer.
Chromatin and MYC-associated PP2A targets
SET directly binds to catalytic PP2Ac subunit of PP2A complex, and inhibits the phosphatase activity against various peptide substrates 24, 25 . SET is also a member of inhibitor of acetyltransferases-complex (INHAT) that binds histones, thus directly preventing their acetylation 47 . In addition to binding core histones, SET has been reported to function as linker histone chaperone 48 .
Interestingly, in our data, functions such as "chromosome organization", "chromatin modifications", and "DNA methylation" ( Fig. 2A) were strongly enriched in the SET targets. As an example, we identified a number of epigenetic regulators to be significantly dephosphorylated in SET-depleted cells: SMARCC2 (S283), KDM1A (S166, S849), SETD2 (S2080, S2082), HDAC1 (S393, S421, S423), CHD3 (S1601, S1605), MTA1 (386, 576) DNMT1
(S714), DOT1L (S1001, S1009) and BRD1 (S1052, S1055) ( Fig. 3A , Table S1 ).
In addition to SET, proteins in the Nurd complex were also found to be regulated by PPP2R1A and PME-1 depletion (Fig. 3A) . These results indicate that inhibition of PP2A-mediated protein dephosphorylation may play a more important role in SET´s chromatin-associated functions than previously anticipated.
The best understood chromatin-associated target for PP2A is transcription factor MYC, and regulation of MYC activity by PP2A has primarily been attributed to dephosphorylation of serine 62 9, 11 . Our data confirmed the approximately 4-fold reduction in the phosphorylation of the peptides containing both T58 and S62 via the depletion of CIP2A, PME-1, or SET ( Fig. 3B ; Table S1 ). On the other hand, depletion of PPP2R1A induced GSK3B (S9) phosphorylation ( Fig. 3B ). This phosphorylation inhibits GSK3B-mediated MYC T58 phosphorylation and thus result in MYC stabilization 49 . We also confirmed proteasome-mediated MYC degradation due to CIP2A depletion (Fig. S2A ).
The pivotal impact of PP2A on the transcriptional activity of MYC was confirmed from the gene set enrichment analysis (GSEA) of the differentially regulated transcripts in CIP2A-depleted HeLa cells (Fig. 3C, S2B ). In this regard, we also identified novel potential mechanisms for direct regulation of the transcriptional activity of MYC. SET was found to regulate phosphorylation of MYC dimerization partner MAX at S2/S11 ( Fig. 3B ; Table S1 ). The phosphorylation of these sites determines the kinetics of MYC/MAX dimer DNA binding. These results reveal SET as a chromatin-associated PP2A inhibitor protein.
Furthermore, the newly identified regulation of MYC DNA binding mechanisms (MAX and MGA), and of chromatin modifying MYC interactors, provide novel mechanistic insight into how PP2A modulates MYC activity in cancer.
Unidirectionality paradigm of phosphoregulation by PP2A
It is generally assumed that phosphorylation sites are under constant equilibrium between kinase and phosphatase activities, and can thus be bidirectionally modulated towards either increased or decreased phosphorylation. However, we made an intriguing observation that the majority of PPP2R1A-regulated peptides (211/320 targets, 66%) were not significantly regulated by the inhibition of CIP2A, PME-1, or SET (Fig. 4A ). The nonoverlapping targets of PPP2R1A and PIPs were reflected also at the level of PP2A-regulated processes that were mostly dominated either by PPP2R1A or by one of the PIPs; and most dominantly by SET ( Fig. 2A) . Even among the processes such as "RNA Processing and Splicing" that were globally controlled by both PPP2R1A and PIPs ( Fig. 2A) , most of the individual peptides were significantly regulated only by either PPP2R1A or by PIPs (Fig. 2B ).
To further examine these provoking results, and to exclude the possibility that these observations were caused by the selection of the statistical criteria for the differentially regulated peptides presented in figures 1 and 2, we performed a soft clustering analysis 53 of the entire dataset of consistently detected peptides.
Consistently with the notion of non-overlapping targets of PPP2R1A and PIPs, in five of the six clusters (clusters 2-6; Fig. 4B ), the majority of the peptides were subject only to unidirectional regulation toward either increased phosphorylation by PPP2R1A inhibition (cluster 2), or increased dephosphorylation by inhibition of PIPs (clusters 3-6; Fig. 4B ). The term unidirectionality is used hereafter to describe a situation where a peptide phosphorylation, or cellular function, is subject to regulation to only one direction by PP2A modulation. On the other hand, cluster 1 was the only cluster in which the same peptides exhibited increased phosphorylation upon PP2A inhibition, and dephosphorylation upon inhibitor protein depletion (i.e., bidirectionality). These results strongly indicate that a large fraction of PP2A target phospho-sites exist in either a nearly fully phosphorylated (kinase dominance; clusters 3-6) or dephosphorylated (phosphatase dominance;
cluster 2) state. Although this unidirectional pattern of phosphorylation regulation has not been previously addressed in relation to phosphatase biology, it is consistent with the reportedly bimodal distribution of global phosphorylation site occupancy 54, 55 .
The unidirectionality paradigm of PP2A target regulation is further supported by analysis of the data for factors with previously reported association with highor low phosphate occupancy. Based on previous work, a higher PP2A/kinase activity ratio is associated rather with threonines than serines [56] [57] [58] , and acidophilic kinase target sites exhibit high phosphate occupancy 55 .
Additionally, phosphorylations on sites in close proximity to each other tend to be phosphorylated in a coordinated fashion by the same kinase, which suggests kinase dominance in regions with high occupancy of adjacent phosphosites 59 . To analyze our data according to these parameters, clusters 1 and 2 (cluster 1&2 hereon), and clusters 5 and 6 (cluster 5&6 hereon) were combined to yield 4 nearly equally sized clusters. By using these four clusters, we found that phosphothreonines were indeed enriched in phosphatasedominant peptides (Fig. 4C) , whereas acidophilic kinase targets (Fig. 4D) , and clustered phosphorylation (peptides with 3 or 4 phosphates) ( Collectively, these analysis reveal unidirectionality paradigm of PP2A target regulation. These novel insights are not only important for general understanding of rules of PP2A-mediated phosphoregulation, but also for realization that all phosphoregulation in cancer cells is not equally susceptible to modulation of PP2A activity. Rather, phosphatase-dominant targets would primarily respond to pharmacological PP2A inhibition 38, 60 , whereas various PP2A reactivation therapies 14, 15 , would primarily affect kinase-dominant targets.
Unidirectional control of canonical pathways
To address how the unidirectionality observed at the peptide level translates to control of cellular activities, we analysed the enrichment of cellular processes and pathways between PP2A target clusters. At the level of cellular process, most of the processes did associate with certain cluster, and followed the pattern of unidirectional regulation (Fig. S3) . However, the processes identified at the peptide level to be regulated by both PP2A inhibition and activation, such as RNA splicing, displayed bidirectional regulation also when assessed at the cluster level (Fig. S3 ). This analysis clearly indicate that the directionality concept of PP2A target regulation is not restricted to individual peptide level, but is relevant to regulation of different cellular processes.
Enrichment of different signalling pathways and kinase targets between different clusters was evaluated by Ingenuity pathway analysis and NetworKIN kinase target prediction tool. As was case with cellular processes, also different signalling pathways displayed notably different distribution between the clusters. Enrichment of PTEN signaling pathway and AKT targets in cluster 1&2
( Fig. 5A, B) , suggests that they are mostly under constitutive dephosphorylation by PP2A. Similarly, Phospholipase C (PLC) signaling, and specifically PKC targets, seem also to follow phosphatase-dominated control as they were found to associate with clusters 1-3 (Fig. 5A, B) . Interestingly, SET phosphorylation by PKC promotes PP2A inhibition 61 , which implies the presence of a positive feedforward loop that promotes PKC signal propagation. In contrast, ERK/MAPK signaling pathway components were enriched in phosphatasedominant cluster 3 (Fig. 5A, B) , indicating a clear difference in directionality rules by which different PP2A target pathways are controlled.
The kinase target motif analyses also revealed that PP2A-regulated CK2 target sites are enriched on clusters 5&6, that constitute of peptides regulated unidirectionally by PIPs, and dominated by SET regulation (Fig. 5B) . This is consistent with previous data indicating functional antagonism between PP2A
and CK2 function 62 , and with role of CK2α as the predominant acidophilic kinase phosphorylating the kinase dominant peptides with multiple phosphorylations (Fig. 5C ).
The dephosphorylation-based regulation of DNA repair mechanisms was strongly apparent from the analysis. Canonical DNA repair-associated pathways (Fig. 5A) , and DNA-PK targets ( (Fig. 5D ). These data are fully consistent with recently emerging data indicating that DNA damage response is a cellular process in which protein dephosphorylation plays a particularly important regulatory role 64 .
The unidirectionality rules revealed by the MS results were confirmed by phospho-motif antibodies. Consistently with the directionality principle, PPP2R1A depletion increased the phosphorylation of different phospho-motifs than those dephosphorylated by SET depletion (Fig. 5E) . Moreover, double knockdown of PPP2R1A and SET rescued majority of dephosphorylations by SET depletion, but had less impact on increased phosphorylation by PPP2R1A depletion (Fig. 5E) , which is consistent with SET modulating PP2A function, and not vice versa.
In summary, these data strongly indicate that unidirectionality of phosphoregulation by PP2A affects entire pathways and biological processes, and thus it constitutes a biologically relevant signaling principle. As exemplified by identification PP2A inhibition as PARPi resistance mechanism, this novel understanding may help in identification of both target processes, as well as clinically relevant therapy combinations for emerging PP2A-targeted cancer therapies.
PP2A activity follows the intracellular cytoplasm-nuclear gradient
In addition to directionality paradigm, cluster analysis of dephosphorylome data revealed several indications for intracellular cytoplasm-nuclear gradient of PP2A target regulation. To examine this previously uncharacterized aspect of PP2A biology, we assessed subcellular protein localization information of the target proteins in different clusters. Notably, the analysis revealed a significant difference in subcellular localization between the targets in different clusters, where the targets from cluster 1&2 (i.e., the phosphatase-dominant peptides)
were dominantly cytoplasmic, whereas the kinase-dominant targets (clusters 4-6) were highly enriched in nuclear proteins (Fig. 6A) . Specifically, the regulation observed in clusters 4 and 5&6, in which PME-1 and SET exhibited a stronger influence on phosphorylation than CIP2A (Fig. 4A ), was consistent with the subcellular localization patterns of these PIPs (Fig. 6B) . The correlation between localization of CIP2A, PME-1, or SET, and the targets they regulate, was apparent also at the level of the differentially regulated peptides, whereas the targets significantly regulated by PPP2R1A depletion were equally distributed between cytoplasm and nucleus (Fig. 6C) . As additional examples, the enrichment of PKC targets in the clusters 1&2, and CK2α targets in the cluster 5&6 (Fig. 4B, 6D ), is consistent with the previously reported predominantly cytoplasmic and nuclear localization of their targets, respectively 65 . Further, nuclear pathways involved in cell cycle checkpoints and, DNA repair and transcriptional repression were associated with clusters 4-6 (Fig. 4A) , that are most dominantly regulated by the nuclear PIPs PME-1 and SET (Fig. 4A,   6A ).
Together these data strongly indicate that PP2A activity is not uniformly distributed in the cell, but comprises of a cytoplasm-nuclear gradient in which PP2A inhibition dominates in the nucleus, whereas cytoplasmic balance is shifted towards phosphatase dominance (Fig. 6D ). This observed phosphorylation gradient is the opposite of the expected gradient for signals originating at the cell membrane and translocating to nucleus under the assumption of uniform phosphatase activity 66 . Therefore, the results suggest that efficient signal propagation in cancer cells requires tight inhibition of nuclear PP2A activity by nuclear PP2A inhibitor protein SET and PME-1 (Fig.   6D ). Further, these results indicate an important role of the spatial distribution of oncogenic PIPs in signal propagation.
The PP2A dephosphorylome both quantitatively and qualitatively defines cancer drug responses
Finally, in order to test functional relevance of PP2A dephosphorylome rules characterized in this study, we exposed the PP2A-modulated cells to drug sensitivity and resistance testing (DSRT) platform 67 . The platform consists of 306 drugs covering all major drug classes from specific kinase inhibitors to DNA-damaging agents and proteosomal inhibitors and thus covers comprehensively different drug-induced biological responses. The cell viability readout of DSRT platform served as a surrogate marker for impact of PP2A modulation to interference with different cellular pathways. The PP2A RNAi treatments were identical to those applied for dephosphorylome profiling and differential drug sensitivity score (ΔDSS) 68 was calculated between the treated and control samples. Among 306 tested drugs, 68 were excluded because they elicited no response in HeLa cells, regardless of the siRNA treatments (Table   S2 ).
The shift in the dephosphorylation balance (Fig. 1B, C) was used as an indicator of PP2A dephosphorylome activity, and the drugs were ranked by uncentered
Pearson's correlations between dephosphorylome activity and the changes in DSSs (Fig. 7A) . The drugs that exhibited synergy with high dephosphorylome activity appear at the top of "correlation rank" (red), whereas the drugs at the bottom exhibited synergy with PP2A inhibition (blue). Furthermore, the enrichment scores were calculated for selected drug groups in the ranked list (Fig. 7A) . The individual drug responses are listed in table S2.
Remarkably, PP2A inhibition by PPP2R1A depletion resulted in increased average drug resistance across all 238 drugs, whereas robust increases in protein dephosphorylation due to the depletion of SET caused the cells to become more drug sensitive on average (Fig. 7A, B) . Interestingly, although the depletion of CIP2A and PME-1 did not influence average drug sensitivity (Fig. 7B) , their effect on sensitivity to individual drugs was in many cases similar to that of SET, albeit of lower magnitudes (Fig. 7A) . This is consistent with the weaker influence of CIP2A and PME-1 on dephosphorylome activity compared to SET (Fig. 1C) . The correlation between overall dephosphorylome activity and drug response was most evident with Aurora kinase (AURK) inhibitors (p=0.0057 for enrichment), and JAK2 inhibitors (p=0.0142) (Fig. 7A ,C, and D).
Interestingly, reflecting the complicated crosstalk between PP2A and mitotic kinases where spatial control contributes to dephosphorylation balance, the bidirectional PP2A activity dependency of the AURK inhibitors was not shared by the other antimitotic drugs (Fig. S4A ). TOP1 inhibitors, but not TOP2B inhibitors, were identified as another class of cancer drugs whose effect correlated with dephosphorylome activity (Fig. 7E) . Further, consistent with other results, PARP inhibitors Olaparib and Rucaparib exhibited clear PP2A-dependency (Table S2 ).
The unidirectionality of PP2A-mediated regulation of drug sensitivity was evident for HDAC and BET bromodomain inhibitors. While PPP2R1A depletion induces significant resistance across all the HDAC and BET inhibitors, increased dephosphorylation activity due to PIP depletion did not confer any drug sensitization (Fig.7F) . This resistance to HDAC and BET inhibition could reflect the apparent role of PP2A in chromatin regulation ( Fig. 2A and 3A) . The
BET inhibitor results are consistent with recently reported role of PP2A inhibition in JQ1 resistance in TNBC 69 . Another interesting unidirectional PP2A dependency was observed for mTOR inhibitors, which in contrast to the majority of drugs, exhibited synergy with PPP2R1A inhibition (Fig. 7G) . The observed sensitization to mTOR inhibitors may reflect an acquired dependency on increased mTOR activity in PPP2R1A-depleted cells, consistent with upregulation of PI3K/AKT/mTOR signaling in these cells (Fig S4B,C) .
Furthermore, the role of SET in mTOR inhibitor resistance was particularly interesting because only ATP-competitive mTOR inhibitors exhibited sensitization upon SET depletion (Fig. 7G ). This finding may be related to the unexpected observation that also SET inhibition caused AKT activation, albeit with differences with PPP2R1A in downstream target phosphorylation (Fig.   S4B,C) .
Together, these data demonstrate a notable overall correlation between PP2A dephosphorylome activity and cellular response to drugs representing all major drug classes. The most important notions however might be that different drug classes can be classified based on their PP2A dependency of response, and that directionality rules apply also to PP2A-dependent drug responses. These aspect may become relevant for developing combination strategies with the emerging PP2A-targeted therapies aiming either to re-activate 14, 15 , or inhibit 38, 60 PP2A.
Discussion
Despite of essential importance of PP2A activity for normal growth and development, as well as its involvement in various diseases, our understanding of PP2A-regulated signaling remains superficial. In this study, we present the largest systematic analysis of PP2A dephosphorylome regulation by the structural PP2A scaffold PPP2R1A, and the three PP2A inhibitor proteins.
Overall the study confirmed the widespread impact of PP2A in cellular phosphopregulation, but also revealed unprecedented rules by which PP2A Another interesting example of PP2A-regulated processes was "Viral life cycle" ( Fig. 2A) which included several viral replication factors and proteins implicated in viral genome transcription (Table S1 ). PP2A-mediated regulation of viral host proteins is particularly interesting as several viruses encode for PP2A inhibitory proteins that specifically interfere with PP2A functions to promote malignant transformation 71 .
Directly related to cancer, but also to many physiological processes, is PP2A-mediated regulation of MYC activity. Thus far PP2A´role in MYC regulation has been tightly linked to regulation of MYC stability via GSK3B and phosphorylation of N-terminal degron containing threonine 58 and serine 62 11 .
We confirm those PP2A-mediated effects, but in addition to that, our results expose an entirely new level of regulation of MYC activity by PP2A-mediated dephosphorylation of MAX, MGA and a number of epigenetic factors that physically associate with MYC at MYC binding sites in chromatin 51 . These results perfectly explain why, despite of its rather modest impact on MYC protein levels (Fig. S2A) , CIP2A depletion has such profound effect on MYCmediated transcriptional activity both in vitro (Fig. 3C) , and in vivo 31 . As inhibition of CIP2A blocks MYC´s proliferation promoting activity in vivo 31 , but PP2A reactivation, either by CIP2A depletion or pharmacologically, do not cause detrimental physiological effects 10, 14, 29, 31 , these results highlight the rational of targeting MYC hyperactivity via PP2A modulation. Notably, although CIP2A is mostly a cytoplasmic protein, the profound effects of CIP2A on MYC activity can be explained by previously published evidence for spatially restricted nuclear lamina-associated domains (LADs) in which CIP2A regulates MYC phosphorylation 31 . With our new data indicating widespread effects of PP2A also on nuclear lamina, these data present another elegant example of coordinated impact of PP2A in cell biology.
In addition to novel information of PP2A-regulated processes and targets, the data also reveal important general concepts related to phosphosignaling. For example, we demonstrate previously unknown differential spatial distribution of kinase-and phosphatase-dominant targets (Fig. 6A, D) and the influence of the amino acid context on the propensity for dephosphorylation (Fig. 4C-E) . The data all together indicate that cellular responses to specific PP2A manipulations are determined by whether the certain phosphosites are either in a kinase-or phosphatase-dominant state. Importantly, we further demonstrate that these rules do not only apply to individual phosphopeptides, but that entire cellular processes are under either kinase or phosphatase dominance (Fig. 5A,B, S3 ).
In addition to broad conceptual importance of appreciating the directionality rules of PP2A-mediated phosphoregulation, this novel information is essential in regards to understanding that not all targets and cellular process are equally amendable for modulation by emerging PP2A-targeted therapies. CIP2A, PME-1, and SET constitute a novel class of human oncoproteins 4, 19, 20 .
Previous work clearly indicated that the oncogenic function of these PIPs is dependent on their PP2A inhibitory function 10, [26] [27] [28] . These proteins also constitute very promising novel cancer therapy targets. However, thus far there has not been systematic understanding of role of these proteins in phosphoproteome regulation, or about their biological redundancies. Based on the obtained data, the differential expression that occurs across human cancer types and the differences in subcellular compartmentalization between PIPs may play important roles in determining their biological redundancy. In addition to these qualitative aspects, the quantitative differences in dephosphorylome regulation by CIP2A, PME-1, and SET are likely explainable by the different functional modes through which these proteins modulate PP2A function 21, 23, 24 .
It is conceivable that the truly non-redundant targets between CIP2A, PME-1, and SET, for the first time systematically analyzed in this study, may explain why only some of these proteins are essential for normal growth and development 29, 32 . These qualitative differences may also be important attributes in assessing the potential and safety of targeting these proteins as a therapeutic approach for the treatment of cancer and other diseases. Analysis of phosphopeptide clusters was carried out similarly. Clusters were compiled by assigning proteins to clusters based on maximum probability. For proteins with multiple identified peptides, we selected the peptide with highest cluster membership (Table S1) . Proteins with B56 binding motif 40 were retrieved from http://slim.ucd.ie/pp2a/ using default search parameters.
Drug sensitivity testing
For the high-throughput DSRT-analyses, cells were transfected 3 days prior to plating them on the drug-containing plates at confluency of 1000 cells/well. The subsequent analyses were carried out as described previously 67 . The differential drug sensitivity score (ΔDSS) 68 was calculated by comparing the response of each siRNA-depleted sample to the average of control samples.
For colony formation assays, 3000 cells in each well on 6-well plate were plated one day after transfections together with drugs, and the assays were performed as described previously 37 . The cells were stained crystal violet similarly to the colony formation assay and the coverage was assessed visually.
Enrichment of drug groups
The numbers of upregulated phosphopeptides for each gene were substracted from the number of downregulated phosphopeptides and the derived difference values were used as PP2A activity index. Uncentered Pearson's correlation coefficients were calculated between the PP2A activity index and DSS drug response values for each drug. Drugs were then ranked by correlation with PP2A activity index. Enrichment scores for selected drug groups in the ranked lists were calculated similarly to Gene Set Enrichment Analysis 80
Cell staining
Proximity ligation assay was performed with Duolink kit (Sigma-Aldrich) according to manufacturer's protocol.
